|1.||Rothstein, David M: 6 articles (05/2008 - 02/2003)|
|2.||Campbell, Lee Ann: 3 articles (01/2009 - 06/2006)|
|3.||Sternlicht, Andrew: 3 articles (10/2007 - 06/2006)|
|4.||Cynamon, M H: 3 articles (11/2000 - 06/2000)|
|5.||Batteiger, Byron E: 2 articles (07/2014 - 08/2007)|
|6.||Suchland, Robert J: 2 articles (05/2008 - 02/2006)|
|7.||van Duzer, John: 2 articles (10/2007 - 11/2006)|
|8.||Stamm, Walter E: 2 articles (08/2007 - 02/2006)|
|9.||Murphy, Christopher K: 2 articles (11/2006 - 06/2006)|
|10.||Chase, S E: 2 articles (11/2000 - 06/2000)|
04/01/1993 - "Moreover, the drug allowed almost complete recovery of infected rabbits by week 7. KRM-1648 cleared infections in the lungs, liver, spleen, and kidneys and restored histopathologic features of healthy tissue in the visceral organs. "
11/01/1994 - "[Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols]."
08/01/1998 - "These findings indicate that suppression of inflammatory reactions using MBST is capable to improve the therapeutic efficacy of KRM-1648 in MAC infection. "
05/01/2008 - "The efficacy of rifalazil and other benzoxazinorifamycins was tested in a mouse model of lung infection against Chlamydia pneumoniae. "
12/01/1995 - "Third, anti-IL-10 antibody augmented to some extent the chemotherapeutic efficacy of KRM-1648 against MAC infection, when the drug was given to mice at weeks 2 and 4 after infection. "
02/01/2002 - "tuberculosis, were resistant to KRM-1648. "
07/01/2001 - "Rifalazil has potent bactericidal activity against Mycobacterium tuberculosis in vitro and in animal models of tuberculosis (TB). "
06/01/2000 - "Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice."
01/01/1997 - "These results suggests that KRM-1648 should further be explored in the treatment of tuberculosis patients."
04/01/1996 - "KRM-1648 showed an excellent chemotherapeutic activity, as compared to RFB and RIF, against drug-susceptible tuberculosis. "
|3.||Mycobacterium avium-intracellulare Infection
02/01/1994 - "[Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice]."
12/01/1993 - "[Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, combined with a immunopotentiator, LC9018, in Mycobacterium intracellulare infection induced in beige mice]."
02/01/1996 - "The in vivo activities of KRM-1648 alone or in combination with both ethambutol (EB) and kanamycin (KM) or clarithromycin (CAM) were tested against Mycobacterium intracellulare infections in beige mice. "
02/01/1996 - "Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice."
|4.||Acquired Immunodeficiency Syndrome (AIDS)
08/01/1994 - "KRM 1648 is a 4-aminobenzoxazine derivative of rifamycin S with potent in vitro activity against the Mycobacterium avium complex (MAC); the MIC for 90% of 24 MAC isolates from AIDS patients was 0.25 microgram/ml as determined by a radiometric broth macrodilution assay. "
02/01/1992 - "This may imply some difficulty with chemotherapy for AIDS-associated MAC infection, even with KRM-1648 treatment, which has excellent in vitro and in vivo anti-MAC activities, as shown in present study."
02/01/1992 - "When the MICs were determined by the agar dilution method with Middlebrook 7H11 agar medium, KRM-1648 exhibited similarly potent in vitro antimicrobial activities against the MAC isolated from AIDS and non-AIDS patients, indicating possible usefulness of KRM-1648 against AIDS-associated MAC infections. "
09/01/1998 - "Rifalazil is a rifamycin derivative from Kaneka that is in phase II clinical trials for the treatment of Mycobacterium tuberculosis (M tuberculosis; TB) and AIDS-associated Mycobacterium avium complex (MAC) infections [108254, 165543]. "
04/01/1993 - "avium complex infections in AIDS patients, was used to evaluate the therapeutic efficacy of KRM-1648, a newly synthesized benzoxazinorifamycin. "
|5.||Peripheral Arterial Disease
01/27/2009 - "The objective of this phase-III trial was to assess the effect of a potent anti-Chlamydial agent, rifalazil, on peak walking time in patients with symptomatic peripheral artery disease. "
01/27/2009 - "No benefit of rifalazil therapy was found in the primary or any secondary end point among this cohort of patients with peripheral artery disease. "
10/01/2007 - "A pivotal clinical trial with rifalazil has been initiated for the treatment of peripheral arterial disease. "
06/01/2006 - "A pivotal clinical trial with rifalazil has been initiated for the treatment of peripheral arterial disease. "
01/27/2009 - "Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1)."
|4.||Anti-Bacterial Agents (Antibiotics)
|10.||Dihydrotachysterol (AT 10)
|1.||Chinese Traditional Medicine (Traditional Chinese Medicine)
|2.||Drug Therapy (Chemotherapy)